Return
Company Page
ai3Bio
Founders
ai3Bio is a biotechnology company targeting autoimmune disease at its cellular root by precisely eliminating disease-causing Th17 cells in vivo. Its dual proprietary platforms, STARx (lipid nanoparticle mRNA delivery) and T Deplete (antibody-based), are designed to reset the immune system in a single step rather than broadly suppressing inflammation. Formed in June 2026 from the merger of Corner Therapeutics' autoimmune technology and UPMC-backed Novasenta, the company is advancing toward first-in-human clinical trials.
Company Founded in 2026
Healthtech & Biotech